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ABSTRACT 
Drug-related hepatotoxicity is the leading cause of acute liver failure, and hepatic problems 
are responsible for a significant number of liver transplantations and deaths worldwide. Cal-
cium has been associated with various metabolic processes that lead to cell death and apopto-
sis, and increased cytosolic Ca2+ has been implicated in hepatotoxicity. This study was de-
signed to investigate the effects of calcium channel blockers (CCBs) on isoniazid-rifampicin, 
zidovudine and erythromycin-induced hepatotoxicity in rats. Treatment groups comprised 
control, hepatotoxicant, hepatotoxicant along with each of silymarin, nifedipine, verapamil 
and diltiazem at subclinical, clinical and supraclinical doses. A day to the end of treatment for 
each model, rats were subjected to the hexobarbitone-induced hypnosis test. On the last days 
of treatment, blood samples were collected and serum was analyzed for relevant biochemical 
parameters. Animals were sacrificed after blood collection and livers were harvested, and 
samples obtained for in vivo antioxidant indices assay and histopathology. The hepatotoxi-
cants significantly increased serum levels of aspartate aminotransferase (AST), alanine ami-
notransferase (ALT) and alkaline phosphatase (ALP), as well as duration of sleep in the hyp-
nosis test. These drugs significantly reduced the hepatic levels of reduced glutathione (GSH), 
superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and increased the 
level of malondialdehyde (MDA). The CCBs at the various doses significantly reversed the 
effects of isoniazid-rifampicin, zidovudine and erythromycin. The results obtained in this 
study suggest that the CCBs possess hepatoprotective activity in drug-induced hepatotoxicity 
and may be beneficial at the subclinical and clinical doses.  
 
Keywords: Calcium channel blockers, drug-induced hepatotoxicity, isoniazid, rifampicin, 
zidovudine, erythromycin 
 
 
INTRODUCTION 
The liver is a vital organ involved in 
detoxification, protein synthesis and pro-
duction of biochemicals essential for the 
process of digestion (e.g. bile). It plays a 
major role in metabolism, glycogen stor-
age, decomposition of red blood cells, 
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plasma protein synthesis, hormone produc-
tion and detoxification. In the process of 
performing its essential role in metabolism 
and detoxification, especially as regards 
exogenous agents, liver damage may oc-
cur. Common causes of liver damage in-
clude xenobiotics, alcohol consumption, 
malnutrition, infection, anemia and medi-
cations (Mroueh et al., 2004). Liver toxici-
ty induced by chemicals is a well recog-
nized problem (Kalantari and Valizadeh, 
2000). According to Satoh (1991), after 
acute exposure, lipid accumulation in the 
hepatocytes, cellular necrosis or hepatobil-
iary dysfunction usually occurs, whereas 
cirrhosis or neoplastic changes are consid-
ered to be the results of chronic exposure. 
Navarro and Senior (2006) defined hepato-
toxicity as injury to the liver that is associ-
ated with impaired liver function caused 
by exposure to drugs or noninfectious 
agents.  
Hepatitis is one of the most prevalent 
diseases in the world and drug related 
hepatotoxicity is the leading cause of acute 
liver failure among patients referred for 
liver transplantation (Lee, 2005; Wang et 
al., 2008). Hepatic problems are responsi-
ble for a significant number of liver trans-
plantations and deaths recorded worldwide 
and available therapeutic options are very 
limited (Akindele et al., 2010). In most 
cases of drug induced hepatotoxicity, there 
is no effective treatment other than cessa-
tion of drug use and general supportive 
care with the possible use of N-
acetylcysteine after acetaminophen over-
dose and intravenous carnitine for 
valproate induced mitochondrial injury 
(Navarro and Senior, 2006; Bohan et al., 
2001; Polson and Lee, 2005). Silymarin, a 
flavonolignan from “milk thistle” (Silybum 
marianum) plant has clinical applications 
in alcoholic liver diseases, liver cirrhosis, 
Amanita mushroom poisoning, viral hepa-
titis, toxic and drug-induced liver disease 
and in diabetic patients, with non-
traditional use in the protection of other 
organs in addition to the liver also being 
advocated (Pradhan and Girish, 2006). 
Due to the wide range of drugs that can 
cause hepatotoxicity (including antibiotic, 
antitubercular, antiviral, anticonvulsant, 
analgesic (non-steroidal anti-inflammatory 
drugs [NSAIDs] and acetaminophen), an-
tihypertensive, antipsychotic, antidepres-
sant and oral contraceptive agents) and the 
increasing incidence and fatality of drug-
induced hepatotoxicity, efforts are ongoing 
worldwide to discover new drugs, espe-
cially from natural products, or find rele-
vant uses for old orthodox drugs. 
Exaggerated calcium influx into cells 
is an important signal that may lead to cell 
death and a number of hepatotoxic effects 
of drugs is associated with increase in in-
tracellular calcium (Thomas and Reed, 
1989; Nicotera et al., 1992; Farghali et al., 
2000). Kristian and Siesjo (1998) reported 
that calcium as a triggering factor has also 
been associated with ischemic cell death. 
According to Nicotera et al. (1992) and 
Gasbarrini et al. (1992), a number of 
hepatocyte injuries is associated with an 
elevation of intracellular calcium and that 
calcium signaling plays a pivotal role in 
the cascade of events that leads to cell in-
jury. Based on these facts, calcium antag-
onism has been explored in the manage-
ment of hepatotoxicity.  
In respect of profiling hepatoprotective 
actions of calcium channel blockers 
(CCBs), Farghali et al. (2000) investigated 
the effects of CCBs on tert-butyl hydro-
peroxide (TBH) induced liver injury using 
isolated perfused rat hepatocytes. The au-
thors concluded that CCBs (verapamil and 
diltiazem) exhibited hepatoprotective 
properties, in hepatocyte oxidative injury, 
accompanied by a decrease in ATPase ac-
tivity, which suggests normalization of 
Ca2+i after TBH intoxication. Sippel et al. 
(1993) demonstrated the modulatory ac-
tion of some CCBs on impaired hepatocyte 
calcium homeostasis induced with dia-
midinothionaphthene (DAMTP). Landon 
et al. (1986) measured calcium in liver 
homogenates and scored tissues for centri-
lobular necrosis 24 h after administration 
of hepatotoxic doses of several chemicals 
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in vivo. Carbon tetrachloride, chloroform, 
dimethylnitrosamine, thioacetamide and 
acetaminophen all caused massive increase 
in hepatocellular calcium content and pro-
duced pericentral necrosis. Administration 
of calcium entry blockers (nifedipine, ve-
rapamil or chlorpromazine) 1 h before or 
7 h after the hepatotoxins significantly at-
tenuated increase in cellular calcium con-
tent and necrosis, thus demonstrating pro-
tective effect against chemical injury in the 
liver in vivo. Kalantari and Valizadeh 
(2000) investigated the protective effect of 
nifedipine against acetaminophen overdose 
(700 mg/kg) induced hepatotoxicity in 
mice. In the study, peak hepatoprotective 
activity was produced by nifedipine at the 
dose of 500 mg/kg.  
The aim of this study was to investi-
gate the effect of subclinical, clinical and 
supraclinical doses of CCBs (nifedipine, 
verapamil and diltiazem) on isoniazid-
rifampicin combination, azidothymidine 
(zidovudine) and erythromycin-induced 
hepatotoxicity in rats. 
 
MATERIALS AND METHODS 
Drugs and chemicals  
Zidovudine (Aurobindo Pharma, Hy-
derabad, India), rifampicin (Mekophar 
Pharmaceutical, Ho Chi Minh City, Viet-
nam), isoniazid (Pfizer Pharmaceuticals, 
Lagos, Nigeria), erythromycin stearate 
(Aurochem Pharmaceuticals Pvt Ltd, 
Mumbai, India), verapamil (APS/Berk 
Pharmaceutical Ltd, Eastbourne, England), 
nifedipine (Gemini Pharmaceuticals, La-
gos, Nigeria), diltiazem (Sanofi-Aventis, 
Milan, Italy), silymarin and hexobarbital 
(Sigma-Aldrich, St Louis, USA).  
 
Animals  
The animals used in this study, 4-6 
weeks old male and female albino rats 
weighing between 150-200 g, were ob-
tained from the Laboratory Animal Center 
of the College of Medicine, University of 
Lagos, Nigeria. The animals were housed 
in polypropylene cages and kept in stand-
ard environmental conditions having ac-
cess to standard rodent feed (Livestock 
Feeds PLC, Lagos, Nigeria) and clean wa-
ter ad libitum. Rats were acclimatized for 
two weeks before the experimental proce-
dures began. 
The experimental procedures were car-
ried out in compliance with the United 
States National Academy of Sciences 
Guide for the Care and Use of Laboratory 
Animals (Committee for the Update of the 
Guide for the Care and Use of Laboratory 
Animals, 2011).  
 
Experimental design  
Isoniazid-rifampicin-induced hepatotoxici-
ty model  
Rats were randomly allotted to 12 dif-
ferent treatment groups (n = 5) as shown in 
Table 1.  
 
Table 1: Treatment groups in the isoniazid-rifampicin-induced hepatotoxicity model 
Group no. Treatment
Group 1 normal saline 10 ml/kg p.o. 
Group 2 isoniazid-rifampicin 100 mg/kg each i.p. 
Group 3 isoniazid-rifampicin 100 mg/kg each i.p. + silymarin 50 mg/kg p.o. 
Group 4 isoniazid-rifampicin 100 mg/kg each i.p. + nifedipine 0.17 mg/kg p.o. (subclinical dose) 
Group 5 isoniazid-rifampicin 100 mg/kg each i.p. + nifedipine 0.86 mg/kg p.o. (clinical dose) 
Group 6 isoniazid-rifampicin 100 mg/kg each i.p. + nifedipine 4.29 mg/kg p.o. (supraclinical dose) 
Group 7 isoniazid-rifampicin 100 mg/kg each i.p. + verapamil 0.86 mg/kg p.o. (subclinical dose) 
Group 8 isoniazid-rifampicin 100 mg/kg each i.p. + verapamil 4.30 mg/kg p.o. (clinical dose) 
Group 9 isoniazid-rifampicin 100 mg/kg each i.p. + verapamil 21.43 mg/kg p.o. (supraclinical dose) 
Group 10 isoniazid-rifampicin 100 mg/kg each i.p. + diltiazem 0.68 mg/kg p.o. (subclinical dose) 
Group 11 isoniazid-rifampicin 100 mg/kg each i.p. + diltiazem 3.43 mg/kg p.o. (clinical dose) 
Group 12 isoniazid-rifampicin 100 mg/kg each i.p. + diltiazem 17.14 mg/kg p.o. (supraclinical dose) 
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Treatment was carried out for 21 days. 
The hepatoxicants and therapeutic inter-
ventions were given concurrently (Bala-
krishnan et al., 2010).  
The clinical dose was calculated as the 
average of the range of doses used for the 
indications of the CCBs. The subclinical 
dose was 1/5th of the clinical dose while 
the supraclinical dose was 5 times the clin-
ical dose.  
 
Zidovudine-induced hepatotoxicity model 
Treatment groups in this test are as 
outlined in Table 1 except that zidovudine 
800 mg/kg p.o. was used in place of isoni-
azid-rifampicin combination to induce 
hepatotoxicity. Administration of drugs 
was carried out for 28 days (Tikoo et al., 
2008). 
 
Erythromycin-induced hepatotoxicity 
model 
In this model erythromycin stearate 
100 mg/kg p.o. was used to induce hepato-
toxicity and the treatment period in respect 
of the groups earlier outlined in Table 1 
was 14 days (Abdel-Hameid, 2007).  
 
Hexobarbitone-induced hypnosis test   
A day before the last administration in 
respect of the models (20th, 27th and 13th 
day for the isoniazid-rifampicin, zidovu-
dine and erythromycin models respective-
ly), rats were subjected to the hexobarbi-
tone-induced hypnosis test for the indirect 
assessment of the level of cytochrome 
P450 metabolizing enzyme activity. Each 
rat in the different groups received hexo-
barbitone 60 mg/kg i.p. Rats were then 
placed on their backs in separate observa-
tion chambers and the duration of loss of 
the righting reflex (starting at the time of 
hexobarbitone injection until they regained 
their righting reflexes) were recorded. The 
recovery of righting reflex was confirmed 
if the animal, when gently placed on its 
back again, rights itself within one minute 
(Vogel and Vogel, 1997; Akindele and 
Adeyemi, 2010). The duration of sleep 
(min) was then recorded for each animal. 
Assessment of parameters  
Two hours after the administration of 
drugs on the last day of treatment for each 
of the models (21st, 28th and 14th day for 
the isoniazid-rifampicin, zidovudine and 
erythromycin models respectively), blood 
samples were collected from each of the 
rats by retro-orbital artery bleeding into 
plain sample bottles. Serum separated out 
by centrifugation at 3000 rpm at 25 °C for 
15 min was used for the estimation of rel-
evant biochemical parameters. After blood 
collection, the animals were sacrificed by 
cervical dislocation and laparatomized for 
the harvest of liver. A slice of approxi-
mately 1/3rd of the liver of each rat was 
processed for estimation of in vivo antiox-
idant indices while the remaining 2/3rd was 
fixed in 10 % formo-saline for histopatho-
logical assessment.  
 
Biochemical analysis  
Levels of alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), total choles-
terol, total bilirubin (TBILI), albumin and 
total protein were estimated using Roche 
and Cobas commercial kits and 
Roche/Hitachi 904 automated analyzer.  
 
Measurement of antioxidant indices  
Measurement of antioxidant indices in 
liver samples including catalase (CAT), 
superoxide dismutase (SOD), glutathione 
peroxidase (GPx), reduced glutathione 
(GSH) and malondialdehyde (MDA) was 
done according to established procedures 
(Soon and Tan, 2002; Habbu et al., 2008) 
Total protein was determined using the 
Biuret method (Gornall et al., 1949).  
 
Histopathological assessment  
The various tissues obtained from ex-
perimental animals fixed in 10 % formo-
saline were dehydrated in graded alcohol, 
embedded in paraffin, and cut into 4-5 μm 
thick sections. Hematoxylin-eosin was 
used to stain the sections for photomicro-
scopic assessment using a Model N-
400ME photomicroscope (CEL-TECH Di-
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agnostics, Hamburg, Germany). Slides 
were examined using the × 40, × 100, and 
× 400 objectives (Galigher and Kozloff, 
1971; Habbu et al., 2008).  
 
Statistical analysis 
Results are expressed as mean ± SEM. 
Data were analyzed using One-way 
ANOVA followed by Dunnett’s multiple 
comparison test using GraphPad Prism 5 
(GraphPad Software Inc., CA, USA). Val-
ues were considered significant when P < 
0.05.  
 
RESULTS 
Isoniazid-rifampicin-induced hepatotoxi-
city model  
Biochemical parameters 
Isoniazid-rifampicin significantly (P < 
0.001) increased the level of AST, ALT 
and ALP while significantly (P < 0.001) 
reducing the level of total protein and al-
bumin (Table 2). Silymarin significantly 
(P < 0.05, 0.001) reduced the level of AST 
and increased the level of total protein 
compared with isoniazid-rifampicin alone 
treated group of animals. Nifedipine at all 
doses administered (subclinical, 0.17 
mg/kg p.o.; clinical, 0.86 mg/ kg p.o.; and 
supraclinical, 4.23 mg/kg p.o.) significant-
ly (P < 0.05, 0.01, 0.001) reduced the level 
of AST and total bilirubin while increasing 
the level of total protein and albumin com-
pared with the isoniazid-rifampicin group, 
with peak effect observed at the clinical 
dose. Verapamil at the clinical (4.29 
mg/kg, p.o.) and supraclinical (21.43 
mg/kg, p.o.) doses significantly (P < 0.05) 
reduced the level of AST, ALT and ALP 
while increasing the level of total protein 
and direct bilirubin compared with isonia-
zid-rifampicin group. There was an in-
crease in total cholesterol at the subclinical 
dose (0.86 mg/kg, p.o.) when compared to 
the hepatotoxicant group. Diltiazem inter-
vention significantly (P < 0.05) reduced 
the levels of AST, ALT and ALP while 
increasing the level of total protein com-
pared with isoniazid-rifampicin alone 
treated group, with effects being most pro-
nounced at the clinical (3.43 mg/kg, p.o.) 
and supraclinical (17.13 mg/kg, p.o.) doses 
(Table 2). 
 
In vivo antioxidant indices 
Isoniazid-rifampicin significantly (P < 
0.05, 0.01) reduced the levels of GSH, 
SOD, CAT and total protein with increase 
in the level of MDA when compared to 
rats of the control group (Table 3). Si-
lymarin significantly (P < 0.05, 0.01) in-
creased the level of GSH and reduced the 
level of MDA relative to the isoniazid-
rifampicin only treated group. Co-
administration of the antitubercular drugs 
with nifedipine significantly (P < 0.05 
0.01) reduced the level of MDA, at all the 
treatment doses, compared to the group of 
rats receiving isoniazid-rifampicin alone. 
However, peak effect was observed at the 
supraclinical dose (4.29 mg/kg, p.o.). At 
this dose, nifedipine also significantly (P < 
0.01) reversed the reduction in GSH level 
induced by isoniazid-rifampicin. Verapam-
il and diltiazem significantly (P < 0.001) 
reduced the level of MDA compared with 
isoniazid-rifampicin only treated group, 
with peak effect produced at the clinical 
doses of 4.29 mg/kg and 3.43 mg/kg re-
spectively (Table 3). 
 
Hexobarbitone-induced hypnosis test 
Isoniazid-rifampicin combination sig-
nificantly (P < 0.01) increased the duration 
of sleep compared with the control group. 
Silymarin and nifedipine at the supraclini-
cal dose (4.29 mg/kg, p.o.) significantly 
reduced the duration of sleep compared 
with the isoniazid-rifampicin alone treated 
group (Table 4). Verapamil and diltiazem 
at the various doses used did not elicit any 
significant effect (P > 0.05) on duration of 
sleep compared to the hepatotoxicant 
group.   
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Table 2: Effect of calcium channel blockers (nifedipine, verapamil and diltiazem) on serum biochemical parameters in isoniazid-rifampicin  
combination-induced hepatotoxicity in rats 
Groups Dose (mg/kg) AST (IU/L) ALT (IU/L) ALP (IU/L) TP (g/L) ALB (g/L) TB (µmol/L) DB (µmol/L) TC (mmol/L)
Control (10 ml/kg) 65.60±4.05 13.20±0.80 9.60±1.15 81.00±2.75 35.80±3.82 6.40±0.67 5.00±2.23 1.64±0.15 
INH-RIF 100 101.60±4.953 22.80±1.153 17.20±1.353 51.20±2.793 23.80±1.653 8.80±0.58 4.80±0.83 1.26±0.05 
SIL + INH-RIF 50/100 79.20±8.60α 16.20±1.35 13.80±0.731 67.20±0.802,γ 24.20±1.652 7.20±0.58 4.80±0.37 1.34±0.05 
NIF + INH-RIF 0.17/100 80.40±8.93α 19.60±1.472 13.40±1.16 63.80±2.693,β 30.20±0.66β 6.20±0.73α 3.40±0.89 1.48±0.11 
 0.86/100 75.00±2.09β 12.60±1.28 10.40±0.50 66.80±2.152, γ 30.20±0.66β 9.00±0.83 3.00±1.22 1.46±0.10 
 4.29/100 74.80±7.44β 14.20±0.96 16.40±3.313 65.21±2.163, γ 29.00±1.09α 9.60±0.402 3.00±0.54 1.64±0.15 
VER + INH-RIF 0.86/100 86.80±4.961 13.40±0.87 14.60±0.812 50.40±0.743 25.20±1.662 7.00±0.632 4.20±0.83 1.70±0.12α 
 4.30/100 85.20±6.62 16.60±1.66γ 11.40±0.81β 49.20±1.853 28.20±1.11 9.40±0.922 5.60±0.40α 1.44±0.11 
 21.43/100 73.40±3.94β 15.40±0.40γ 12.20±0.96β 64.60±1.533,γ 24.60±0.742 10.40±0.40 5.00±0.54α 1.28±0.11 
DIL + INH-RIF 0.68/100 87.00±5.861 15.00±0.40γ 14.00±0.90β 63.00±3.563,α 28.80±0.91 9.60±0.67 4.40±0.50 1.56±0.20 
 3.43/100 70.80±6.62γ 14.00±0.70γ 11.40±0.67β 63.60±2.603,β 24.60±0.742 9.60±0.40 4.20±0.58 1.44±0.23 
 17.14/100 72.00±1.94β 12.20±1.75γ 13.00±1.70 63.80±2.173,β 24.40±1.862 6.80±0.80 5.20±0.66 1.60±0.56 
Data are expressed as mean ± S.E.M. (n = 5). 1P <0.05, 2P < 0.01, 3P < 0.001 vs. control; αP < 0.05, βP < 0.01, γP < 0.001 vs. isoniazid-rifampicin combination 
(One-way ANOVA followed by Dunnett’s multiple comparison test) 
 
 
Table 3: Effect of nifedipine, verapamil and diltiazem on in vivo antioxidant indices in liver samples in isoniazid-rifampicin  
combination-induced hepatotoxicity in rats 
Groups Dose 
(mg/kg) 
GSH
(U/mg protein) 
SOD
(U/mg protein) 
CAT
(U/mg protein) 
GPx
(U/mg protein) 
MDA
(U/mg protein) 
Total protein
(mg) 
Control (10 ml/kg) 5.41±1.89 13.25±2.56 22.26±1.47 4.49±0.37 0.27±0.09 74.15±3.36 
INH-RIF 100 1.04±0.231 1.21±0.143 5.82±1.963 0.58±0.20 1.03±0.133 27.09±2.513 
SIL + INH-RIF 50/100 3.39±0.65 2.53±0.723 8.86±4.242 0.49±0.21 0.09±0.02γ 36.21±7.842 
NIF + INH-RIF 0.17/100 2.20±0.26 1.65±0.433 9.01±1.792 0.52±0.13 0.15±0.06γ 30.05±5.223 
 0.86/100 2.25±0.36 2.22±0.813 9.26±3.042 0.69±0.25 0.11±0.01γ 28.85±7.663 
 4.29/100 4.46±1.35β 1.87±0.653 4.70±1.183 0.38±0.04 0.07±0.11γ 33.66±8.993 
VER + INH-RIF 0.86/100 2.04±0.371 1.56±0.683 9.57±3.851 0.79±0.22 0.21±0.03γ 21.65±1.832 
 4.30/100 2.43±0.48 1.91±0.763 9.57±3.86 0.60±0.23 0.17±0.16γ 68.54±14.08 
 21.43/100 1.82±0.421 2.89±1.223 15.19±6.53 0.91±0.38 0.22±0.04γ 39.09±13.26 
DIL + INH-RIF 0.68/100 2.70±0.80 2.09±1.083 6.22±2.133 0.65±0.33 0.09±0.00γ 38.27±10.953 
 3.43/100 1.40±0.161 1.94±0.543 6.02±1.683 0.63±0.17 0.05±0.16γ 51.81±4.022 
 17.14/100 2.77±0.48 2.26±0.553 8.40±1.842 12.5±1.40 0.17±0.03γ 12.50±1.403 
Data are expressed as mean ± S.E.M. (n = 5). 1P <0.05, 2P < 0.01, 3P < 0.001 vs. control; βP < 0.01, γP < 0.001 vs. isoniazid-rifampicin combination  
(One-way ANOVA followed by Dunnett’s multiple comparison test)
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Table 4: Effect of nifedipine, verapamil and dilti-
azem on duration of sleep in hexobarbitone-
induced hypnosis test in isoniazid-rifampicin 
combination-induced hepatotoxicity in rats  
Groups Dose 
(mg/kg) 
Duration of sleep 
(min) 
Control (10 ml/kg) 6.60±2.75 
INH-RIF 100 16.00±3.112 
SIL + INH-RIF 50/100 6.62±1.22β 
NIF + INH-RIF 0.17/100 13.75±2.691 
 0.86/100 11.25±1.57 
 4.29/100 10.63±3.67α 
VER + INH-RIF 0.86/100 13.13±3.43 
 4.30/100 14.88±3.09 
 21.43/100 12.25±2.22 
DIL + INH-RIF  0.68/100 8.87±0.872 
 3.43/100 8.00±1.292 
 17.14/100 7.62±1.482 
Data are expressed as mean ± S.E.M. (n = 5). 
1P < 0.05, 2P < 0.01 vs. control; αP <0.05, βP < 
0.01 vs. isoniazid-rifampicin combination (One-
way ANOVA followed by Dunnett’s multiple 
comparison test) 
 
 
Zidovudine-induced hepatotoxicity model 
Biochemical parameters  
Significant (P < 0.01, 0.001) increase in 
the levels of AST, ALT, ALP and total bili-
rubin but significant (P < 0.01) reduction in 
the level of total protein were observed in 
the zidovudine treated rats compared to con-
trol (Table 5). Silymarin significantly (P < 
0.05, 0.01) reversed the effect of zidovudine 
on ALP and total bilirubin. Nifedipine at the 
clinical dose (0.86 mg/kg, p.o.) and supra-
clinical dose (4.29 mg/kg, p.o.) produced 
significant (P < 0.05, 0.01) reduction in the 
levels of AST and ALP compared to the zi-
dovudine treated group. Verapamil at the 
supraclinical dose (21.43 mg/kg, p.o.) sig-
nificantly (P < 0.05, 0.01) reduced the level 
of AST and increased the level of total pro-
tein relative to the zidovudine only group. In 
respect of diltiazem, there was significant (P 
< 0.05, 0.01, 0.001) reduction in the levels 
of AST and total bilirubin while the level of 
total protein was significantly (P < 0.05, 
0.01) increased compared to the zidovudine 
treated rats, at all doses used. However, peak 
protective effect was elicited at the subclini-
cal dose, 0.68 mg/kg, p.o. (Table 5). 
 
In vivo antioxidant indices  
Zidovudine (800 mg/kg, p.o.) caused 
significant (P < 0.01) reductions in the lev-
els of GSH, SOD, CAT, GPx and total pro-
tein in liver samples but the level of MDA 
was significantly (P < 0.001) increased 
compared to control (Table 6). Silymarin 
(50 mg/kg, p.o.) significantly (P < 0.05, 
0.01, 0.001) reversed the effect of zidovu-
dine on these parameters especially as it re-
lates to GSH, CAT and MDA. Nifedipine at 
the subclinical dose (0.17 mg/kg, p.o.), clin-
ical dose (0.86 mg/kg, p.o.) and supraclini-
cal dose (4.23 mg/kg, p.o.) reversed the ele-
vation in the levels of MDA produced by 
zidovudine, with peak protective effect ob-
served at the clinical dose. However, the 
level of CAT observed with nifedipine at the 
clinical and supraclinical doses were signifi-
cantly (P < 0.05, 0.01) lower when com-
pared with the zidovudine only treated rats. 
Verapamil at all doses (subclinical, 0.86 mg/ 
kg; clinical, 4.29 mg/kg; and supraclinical, 
21.43 mg/kg, p.o.) significantly (P < 0.01, 
0.001) reversed the elevation of MDA level 
produced by zidovudine. Verapamil also 
significantly (P< 0.05) increased the levels 
of SOD at the clinical dose but there was a 
significant (P < 0.01) reduction in CAT lev-
el at the supraclinical dose compared to zi-
dovudine. Diltiazem at the supraclinical 
dose (4.23 mg/kg, p.o.) significantly (P < 
0.05, 0.01) increased zidovudine diminished 
level of GSH, with a reversal of the in-
creased level of MDA observed with zidov-
udine (Table 6). 
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Table 5: Effect of calcium channel blockers (nifedipine, verapamil and diltiazem) on serum biochemical parameters in zidovudine-induced  
hepatotoxicity in rats 
Groups Dose (mg/kg) AST (IU/L) ALT (IU/L) ALP (IU/L) TP (g/L) ALB (g/L) TB (µmol/L) DB (µmol/L) TC (mmol/L)
Control (10 ml/kg) 65.60±4.05 13.20±0.80 12.00±1.15 81.00±2.75 35.80±3.82 6.40±0.67 5.00±1.00 1.64±0.15 
ZID 800 144.00±10.303 28.80±2.552 40.00±4.623 49.20±5.862 27.40±2.35 12.60±0.923 3.20±0.37 1.38±0.09 
SIL + ZID 50/800 113.80±8.603 20.00±2.44 26.40±26.602,α 62.40±2.61 27.60±2.33 7.40±1.03β 3.00±0.44 1.56±0.10 
NIF + ZID 0.17/800 137.60±8.933 27.00±2.932 37.20±3.313 62.80±5.84 24.60±2.351 13.20±1.153 3.20±0.37 1.36±0.06 
 0.86/800 85.80±4.40β 28.80±3.912 24.80±4.481,α 55.00±6.632 28.00±2.19 9.00±0.83 3.40±0.54 1.46±0.14 
 4.29/800 112.40±8.582,α 20.20±1.42 31.00±3.313 50.40±6.632 28.00±2.19 9.00±0.83 3.00±0.44 1.56±0.22 
VER + ZID 0.86/800 130.60±4.473 25.60±2.612 34.20±3.663 61.00±8.471 32.60±4.72 8.40±1.15 2.80±0.37 1.60±0.17 
 4.30/800 122.80±12.903 27.40±1.603 32.60±4.463 61.20±5.05 22.80±1.651 9.40±1.32 3.80±0.66 1.50±0.20 
 21.43/800 80.20±2.97γ 26.40±2.992 34.60±4.103 71.80±4.34α 28.80±1.59 10.60±1.431 3.20±0.37 1.32±0.10 
DIL + ZID 0.68/800 75.60±4.16γ 25.60±2.832 34.60±3.253 70.80±3.30β 29.00±2.09 8.60±0.97α 3.60±0.50 1.84±0.22 
 3.43/800 89.60±6.70γ 28.20±3.203 33.40±2.443 67.00±3.53α 27.40±3.05 10.00±0.701 3.60±0.51 1.26±0.16 
 17.14/800 100.40±8.031,β 27.40±1.282 35.60±3.613 68.60±4.28α 26.40±1.63 9.20±1.24 3.20±0.37 1.52±0.13 
Data are expressed as mean ± S.E.M. (n = 5). 1P < 0.05, 2P < 0.01, 3P < 0.001 vs. control; αP < 0.05, βP < 0.01, γP < 0.001 vs. zidovudine (One-way ANOVA 
followed by Dunnett’s multiple comparison test) 
 
Table 6: Effect of nifedipine, verapamil and diltiazem on in vivo antioxidant indices in liver samples in zidovudine-induced hepatotoxicity in rats 
Groups Dose (mg/kg) GSH (U/mg protein) SOD (U/mg protein) CAT (U/mg protein) GPx (U/mg protein) MDA (U/mg protein) Total protein (mg) 
Control (10 ml/kg) 5.41±1.89 13.25±2.56 22.26±1.47 4.49±0.37 0.27±0.09 74.15±3.36 
ZID 800 0.78±0.122 5.59±1.182 12.91±1.463 1.75±0.372 1.20±0.113 29.72±5.162 
SIL + ZID 50/800 4.36±0.83α 6.25±0.832 20.21±2.46β 2.02±0.362 0.30±0.02γ 59.86±3.552 
NIF + ZID 0.17/800 0.73±0.232 6.71±1.181 10.11±1.133 2.16±0.322 0.17±0.02γ 48.27±4.582 
 0.86/800 1.51±0.521 5.24±1.082 3.58±0.793,β 1.64±0.332 0.11±0.03γ 74.15±20.352 
 4.29/800 2.30±0.43 4.23±0.563 6.61±1.183,α 1.32±0.813 0.47±0.13γ 30.66±3.493 
VER + ZID 0.86/800 3.35±1.40 9.75±2.231 20.74±3.15 3.05±0.70 0.60±0.09β 22.44±3.313 
 4.30/800 2.33±0.70 9.75±1.031,α 14.88±1.36 2.99±1.31 0.57±0.06β 27.88±5.113 
 21.43/800 3.12±1.44 8.25±1.25 4.39±1.363,β 0.20±0.032 0.48±0.18γ 47.39±9.442 
DIL + ZID 0.68/800 3.69±0.60 6.31±0.531 8.17±1.333 1.98±0.32 0.92±0.36 32.14±11.141 
 3.43/800 2.68±0.39 7.75±10.25 10.25±2.892 2.03±0.27 0.54±0.14 51.57±18.003 
 17.14/800 6.32±2.49α 10.03±2.20 16.98±2.48 5.42±3.20 0.14±0.02β 27.91±11.751 
Data are expressed as mean ± S.E.M. (n = 5). 1P < 0.05, 2P < 0.01, 3P < 0.001 vs. control; αP < 0.05, βP < 0.01, γP < 0.001 vs. zidovudine (One-way ANOVA  
followed by Dunnett’s multiple comparison test)
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Hexobarbitone-induced hypnosis test  
Significant (P < 0.01) increase in the du-
ration of sleep was observed in the zidovu-
dine treated group of rats compared to the 
control group. Silymarin and the CCBs at all 
doses used did not significantly (P > 0.05) 
affect the duration of sleep compared to the 
zidovudine only group (Table 7). 
 
 
Table 7: Effect of nifedipine, verapamil and dilti-
azem on duration of sleep in hexobarbitone-
induced hypnosis test in zidovudine-induced 
hepatotoxicity in rats 
Groups Dose 
(mg/kg) 
Duration of 
sleep (min) 
Control (10 ml/kg) 6.60±2.75 
ZID 800 23.20±3.482 
SIL + ZID 50/800 12.20±3.66 
NIF + ZID 0.17/800 21.00±3.051 
 0.86/800 12.80±3.83 
 4.29/800 16.80±3.21 
VER + ZID 0.86/800 21.80±5.51 
 4.30/800 25.00±4.331 
 21.43/800 13.00±3.67 
DIL + ZID  0.68/800 15.40±2.52 
 3.43/800 9.60±3.07 
 17.14/800 13.80±5.97 
Data are expressed as mean ± S.E.M (n = 5). 1P 
< 0.05, 2P < 0.01 vs. control (One-way ANOVA 
followed by Dunnett’s multiple comparison test) 
 
 
Erythromycin-induced hepatotoxicity  
model  
Biochemical parameters  
As shown in Table 8, erythromycin 
caused a significant (P < 0.01, 0.001) in-
crease in serum ALT and AST levels when 
compared to the control group. Silymarin 
produced a decrease in AST and ALT levels 
compared to the erythromycin group but the 
effect was only significant (P < 0.01) in re-
spect of AST. Treatment with the CCBs re-
duced the elevated levels of AST and ALT 
but the effect was only significant (P < 0.05) 
in respect of AST. Nifedipine administered 
at the subclinical dose of 0.17 mg/kg pro-
duced the most pronounced effect with the 
effect of verapamil at the clinical dose of 
4.30 mg/kg also being significant (P < 0.05). 
Erythromycin also caused a significant (P < 
0.001) increase in serum ALP level com-
pared to the control group. Silymarin and the 
CCBs produced significant reductions (P < 
0.001) in ALP level compared to erythro-
mycin. Diltiazem at the clinical dose of 3.43 
mg/kg produced the most pronounced effect. 
Erythromycin had no significant effect (P > 
0.05) on total protein compared to the con-
trol. Silymarin produced a significant (P < 
0.05) reduction in the level of total protein 
compared to erythromycin. The CCBs did 
not produce any significant effect (P > 0.05) 
on total protein compared to the erythromy-
cin group (Table 8). Erythromycin produced 
a significant (P < 0.01) increase in albumin 
level when compared to control. Silymarin 
produced a significant (P < 0.05) reduction 
in the level of albumin compared to eryth-
romycin. The CCBs did not generally pro-
duce a significant effect on serum albumin 
compared to the erythromycin group except 
in the case of verapamil at the clinical dose 
of 4.30 mg/kg in which there was a signifi-
cant (P < 0.001) reduction (Table 8). In re-
spect of total bilirubin, direct bilirubin and 
cholesterol, there was no significant differ-
ence in comparing erythromycin with con-
trol and in comparing silymarin and the 
CCBs with erythromycin except in the case 
of verapamil at the subclinical dose of 0.86 
mg/kg in which a significant (P < 0.001) 
increase in total bilirubin was produced 
compared to erythromycin (Table 8). 
 
In vivo antioxidant indices  
Erythromycin reduced the level of GSH 
compared to control but this effect was not 
significant (P > 0.05). Silymarin, verapamil 
at the subclinical dose of 0.86 mg/kg, and 
diltiazem at the clinical dose of 3.43 mg/kg 
reversed the effect of erythromycin by sig-
nificantly (P < 0.05) increasing the level of 
EXCLI Journal 2013;12:231-250 – ISSN 1611-2156 
Received: September 04, 2012, accepted: March 04, 2013, published: March 14, 2013 
 
240 
GSH. Nifedipine at all the doses used, vera-
pamil at 4.30 and 17.40 mg/kg, and dilti-
azem at 0.68 and 17.14 mg/kg did not pro-
duce any significant effect on GSH level 
compared to erythromycin (Table 9). Eryth-
romycin did not produce any significant ef-
fect (P > 0.05) on SOD, CAT, GPx, and 
MDA compared to control. Silymarin and 
the CCBs also did not produce any signifi-
cant (P > 0.05) effect on these parameters 
relative to erythromycin (Table 9). Erythro-
mycin increased the level of total protein in 
liver samples but this effect was not signifi-
cant (P > 0.05) compared to the control. 
Compared to erythromycin, silymarin re-
duced the level of total protein but this effect 
was also not significant (P > 0.05). Nifedi-
pine at the supraclinical dose of 4.29 mg/kg 
and verapamil at the clinical and supraclini-
cal doses of 4.30 mg/kg and 17.30 mg/kg 
respectively, significantly (P < 0.01, 0.001) 
increased the total protein level compared to 
erythromycin. However, diltiazem at the 
clinical dose of 3.43 mg/kg significantly (P 
< 0.05) reduced the total protein level com-
pared to erythromycin (Table 9). 
 
Hexobarbitone-induced hypnosis test   
In relation to control, erythromycin sig-
nificantly (P < 0.001) increased the duration 
of sleep. Silymarin and the CCBs at all dos-
es used significantly (P < 0.001) reduced the 
duration of sleep compared to erythromycin. 
The effect of the CCBs in preserving the 
metabolizing effect of cytochrome P450 en-
zymes on hexobarbitone was most pro-
nounced for nifedipine at the subclinical 
dose of 0.17 mg/kg, for verapamil at the 
clinical dose of 4.30 mg/kg, and for dilti-
azem at the subclinical dose of 0.68 mg/kg 
(Table 10).  
 
Histopathological assessment 
Hepatotoxicants representative samples 
presented with cytoplasmic inclusions with 
frosted appearance of hepatocytes due to 
intracellular accumulation of material, and 
periportal hemorrhage with the observation 
of presence of blood around the portal tracts. 
Control, silymarin, and CCBs intervention 
representative samples generally presented 
as normal liver with hepatocytes arranged as 
plates radiating away from the central vein 
to the portal tracts. Representative photomi-
crographs are presented as Figures 1A-F. 
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Table 8: Effect of calcium channel blockers (nifedipine, verapamil and diltiazem) on serum biochemical parameters in erythromycin-induced hepa-
totoxicity in rats 
Groups Dose (mg/kg) AST (IU/L) ALT (IU/L) ALP (IU/L) TP (g/L) ALB (g/L) TB (µmol/L) DB (µmol/L) TC (mmol/L)
Control (10 ml/kg) 50.00 ± 2.50 8.60 ± 0.40 18.80 ± 0.70 63.40 ± 4.30 29.60 ± 0.20 8.40 ± 0.20 4.00 ± 0.50 1.60 ± 0.20 
ERT 100 78.80 ± 5.101 27.40 ± 3.803 113.20 ± 4.101 68.00 ± 1.60 34.00 ± 1.401 7.40 ± 0.80 3.80 ± 0.80 2.00 ± 0.30 
SIL + ERT 50/100 50.40 ± 7.10β 18.40 ± 0.70 51.60 ± 4.90γ,2 66.60 ± 3.60α 29.20 ± 0.50α 6.20 ± 1.00 2.40 ± 0.40 2.20 ± 0.10 
NIF + ERT 0.17/100 55.40 ± 2.10α 21.80 ± 3.401 39.00 ± 6.00γ 65.60 ± 1.40 33.80 ± 0.501 6.20 ± 0.70 3.00 ± 0.50 2.30 ± 0.40 
 0.86/100 68.40 ± 4.45 24.20 ± 3.902 59.80 ± 11.70γ,3 68.40 ± 1.70 30.60 ± 0.70 6.20 ± 1.00 2.80 ± 0.90 2.10 ± 0.30 
 4.29/100 67.40 ± 5.601 21.60 ± 3.701 26.40 ± 4.00γ 69.80 ± 3.80 31.40 ± 0.70 7.20 ± 0.70 2.80 ± 0.40 2.50 ± 0.40 
VER + ERT 0.86/100 76.00 ± 4.702 29.60 ± 5.102 34.60 ± 3.50γ 71.60 ± 1.70 32.00 ± 1.30 6.40 ± 0.70γ  2.60 ± 0.40 2.50 ± 0.40 
 4.30/100 57.40 ± 3.10α 24.60 ± 5.901 35.20 ± 3.90γ 70.40 ± 3.60 31.80 ± 1.30γ 7.20 ± 0.20 2.60 ± 0.30 1.80 ± 0.20 
 21.43/100 78.40 ± 6.702 23.60 ± 4.30 27.60 ± 9.20γ 66.20 ± 0.60 33.00 ± 1.10 7.00 ± 0.70 3.00 ± 0.60 2.50 ± 0.20 
DIL + ERT 0.68/100 70.40 ± 3.30 29.00 ± 6.102 34.80 ± 3.10γ 75.60 ± 2.701 35.80 ± 1.203 6.40 ± 0.80 3.20 ± 0.60 2.20 ± 0.40 
 3.43/100 73.40 ± 5.70 25.40 ± 4.901 23.60 ± 5.70γ 69.60 ± 2.80 32.80 ± 1.00 7.20 ± 1.00 3.20 ± 0.50 2.50 ± 0.30 
 17.14/100 72.40 ± 12.70 20.00 ± 3.70 33.00 ± 7.80γ 69.40 ± 1.90 31.20 ± 0.80 6.80 ± 0.80 3.40 ± 0.80 1.30 ± 0.10 
Data are expressed as mean ± S.E.M. (n = 5). 1P < 0.05, 2P < 0.01, 3P < 0.001 vs. control; αP <0.05, βP < 0.01, γP < 0.001 vs. erythromycin  
(One-way ANOVA followed by Dunnett’s multiple comparison test) 
 
Table 9: Effect of nifedipine, verapamil and diltiazem on in vivo antioxidant indices in liver samples in erythromycin-induced hepatotoxicity in rats 
Groups Dose 
(mg/kg) 
GSH 
(U/mg protein) 
SOD
(units/mg protein) 
CAT
(units/mg protein) 
GPx 
(units/mg protein) 
MDA
(units/mg protein) 
Total protein
(mg)  
Control 
 
(10 ml/kg) 1.80 ± 0.69 3.79 ± 0.73 14.31 ± 3.57 1.18 ± 0.23 0.30 ± 0.11 16.14 ± 1.54 
ERT 100 0.59 ± 0.32 2.73 ± 1.15 12.86 ± 5.26 0.86 ± 036 0.13 ± 0.02 38.54 ± 8.06 
SIL + ERT 50/100 2.19 ± 0.40α 3.23 ± 0.48 11.60 ± 1.16 1.02 ± 0.15 0.34 ± 0.19 17.88 ± 3.31 
NIF + ERT 0.17/100 0.79 ± 0.30 7.52 ± 1.70 21.44 ± 4.25 2.36 ± 0.53 0.14 ± 0.03 23.32 ± 3.11 
 0.86/100 0.53 ± 0.18 8.20 ± 3.76 9.56 ± 1.36 2.57 ± 1.18 0.14 ± 0.06 32.42 ± 4.41 
 4.29/100 1.02 ± 0.68 3.19 ± 0.78 10.08 ± 4.72 1.00 ± 0.24 0.18 ± 0.09 104.80 ± 21.94β,3 
VER + ERT 0.86/100 1.75 ± 0.36α 3.35 ± 1.69 12.01 ± 4.19 1.05 ± 0.53 0.08 ± 0.03 55.11 ± 7.721 
 4.30/100 0.85 ± 0.23 2.01 ± 0.75 8.50 ± 3.66 0.63 ± 0.24 0.12 ± 0.03 94.70 ± 21.36β,3 
 21.43/100 0.44 ± 0.06 1.33 ± 0.39 4.32 ± 0.95 0.42 ± 0.12 0.06 ± 0.01 127.00 ± 3.37γ,3 
DIL+ ERT 0.68/100 1.97 ± 0.42 3.24 ± 0.22 9.12 ± 3.11 0.60 ± 0.12 0.27 ± 0.1 30.44 ± 4.97 
 3.43/100 2.51 ± 0.52α 3.24 ± 0.22 14.63 ± 1.16 1.02 ± 0.07 0.21 ± 0.1 18.10 ±1.77α 
 17.14/100 1.66 ± 0.29 2.73 ± 0.95 15.48 ± 4.64 0.86 ± 0.3 0.18 ± 0.04 28.49 ± 6.13 
Data are expressed as mean ± S.E.M. (n=5). 1P < 0.05, 2P < 0.001 vs. control; αP < 0.05, βP < 0.01, γP < 0.001 vs. erythromycin  
(One-way ANOVA followed by Dunnett’s multiple comparison test) 
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Figure 1: Representative photomicrographs of liver samples. A. control group (normal saline 10 ml/kg, p.o.) showing normal liver architecture; B. isoniazid-
rifampicin group (100 mg/kg each, p.o.) showing cytoplasmic inclusions; C. Silymarin (50 mg/kg, p.o.) + isoniazid-rifampicin (100 mg/kg each, p.o.) group showing 
normal liver; D. Nifedipine (clinical dose; 0.86 mg/kg, p.o.) + isoniazid-rifampicin (100 mg/kg each, p.o.) group showing normal liver; E. Zidovudine (800 mg/kg, 
p.o.) group showing periportal hemorrhage; F. Verapamil (clinical dose; 4.30 mg/kg, p.o.) + zidovudine (800 mg/kg, p.o.) group showing normal liver (×400) 
A 
B 
C 
D E F 
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Table 10: Effect of nifedipine, verapamil and 
diltiazem on duration of sleep in hexobarbitone-
induced hypnosis test in erythromycin-induced 
hepatotoxicity in rats 
Groups Dose 
(mg/kg) 
Duration of 
sleep (min) 
Control (10 ml/kg) 19.20 ± 1.63 
ERT 100 28.20 ± 0.923 
SIL + ERT 50/100 10.60 ± 1.17γ,3 
NIF + ERT 0.17/100 6.20 ± 0.58γ,3 
 0.86/100 12.40 ± 1.03γ,3 
 4.29/100 15.60 ± 0.98γ 
VER + ERT 0.86/100 18.20 ± 1.69γ 
 4.30/100 10.25 ± 1.85γ,2 
 21.43/100 15.00 ± 2.89γ 
DIL + ERT  0.68/100 6.67 ± 0.88γ,2 
 3.43/100 14.67 ± 1.67β 
 17.14/100 13.00 ± 4.12γ 
Data are expressed as mean ± S.E.M. (n=5). 2P 
< 0.01, 3P < 0.001 vs. control; βP < 0.01, γP < 
0.001 vs. erythromycin (One-way ANOVA fol-
lowed by Dunnett’s multiple comparison test) 
 
 
DISCUSSION 
Drug-induced liver injury is a potential 
complication of nearly every prescribed 
medication and many fatal and near-fatal 
drug reactions occur each year (Kaplowitz, 
1992; Zimmerman and Maddrey, 1993; 
Farrell, 1994; Lee, 1995). According to 
Pandit et al. (2012), more than 900 drugs, 
toxins and herbs have been reported to 
cause liver injury, and drug-induced liver 
injury is responsible for 5 % of all hospital 
admissions and 50 % of all acute liver fail-
ures. More than 75 % of cases of idiosyn-
cratic drug reactions result in liver trans-
plantation or death (Ostapowicz et al., 
2002). Drug-induced liver injury is reported 
to be the most common reason for drug 
withdrawal from the market (Pandit et al., 
2012). With increasing morbidity and mor-
tality arising from drug-induced liver inju-
ry, a lot of attention is being devoted 
worldwide to understanding the mechanis-
tic basis of drug-induced hepatotoxicity, 
strategy for management, and search for 
drugs (complementary or orthodox; natural 
or synthetic; old or new) that may amelio-
rate or reverse drug-induced liver injury by 
chemically or therapeutically diverse 
agents. Among the numerous drugs reputed 
to induce hepatotoxicity are the antitubercu-
lar drugs isoniazid and rifampicin, antiviral 
drug zidovudine, and antibiotic erythromy-
cin.  
Isoniazid and rifampicin are first-line 
anti-tuberculosis chemotherapeutic agents 
that have been associated with hepatotoxici-
ty. A major metabolic pathway of isoniazid 
is acetylation to acetylisoniazid and subse-
quent hydrolysis to acetylhydrazine and 
isonicotinic acid (Tostmann et al., 2008). 
Acetylhydrazine is either hydrolyzed to hy-
drazine or acetylated to diacetylhydrazine 
(Ellard and Gammon, 1976; Mitchell et al., 
1976). Hydrazine has been suggested as the 
toxic metabolite of isoniazid responsible for 
its hepatotoxicity (Gent et al., 1992; Sarich 
et al., 1996). Hydrazine is known to cause 
irreversible cellular damage (Tostmann et 
al., 2008) and a study in rat liver micro-
somes showed that nitrogen-centered radi-
cals are formed during hydrazine metabo-
lism which possibly participates in the 
hepatotoxicity process (Noda et al., 1985). 
Rifampicin undergoes desacetylation to 
desacetylrifampicin and hydrolysis to pro-
duce 3-formylrifampicin (Acocella and 
Conti, 1980; Holdiness, 1984). The mecha-
nism of rifampicin-induced hepatotoxicity 
is unknown (Tostmann et al., 2008) and 
there is no evidence for the presence of tox-
ic metabolites (Westphal et al., 1994). 
However, rifampicin is a potent inducer of 
hepatic CYP450 and induction of isoniazid 
hydrolase results in increased hydrazine 
production when rifampicin is combined 
with isoniazid resulting in higher toxicity 
(Blair et al., 1985; Sarma et al., 1986).  
Zidovudine is a potent inhibitor of HIV 
replication and the first clinically approved 
drug for AIDS (Tikoo et al., 2008). Several 
antiretrovirals, including zidovudine, have 
been reported to cause fatal acute hepatitis 
(Pandit et al., 2012). Mechanisms that have 
been suggested for zidovudine-induced tox-
icity include alteration in liver mitochondri-
al DNA, alteration in oxidative phosphory-
lation coupling and changes in fine ultra-
structure of liver mitochondrial (Tikoo et 
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al., 2008). Generation of reactive oxygen 
species (ROS), peroxide production and 
oxidative damage in mitochondria have 
been reported to play vital roles in zidovu-
dine-induced toxicity (Majid et al., 1991; 
Tikoo et al., 2008).  
Erythromycin is a commonly used anti-
biotic which induces severe liver injury and 
cardiovascular dysfunction both in humans 
and experimental animals at high doses 
(Adams, 1976; Pari and Murugan, 2004). 
As reported by Pessayre et al. (1985), over-
doses of erythromycin led to occurrence of 
hepatitis, hepatic dysfunction, jaundice and 
necrosis of hepatocytes. Erythromycin is 
metabolized to reactive nitrosoalkane de-
rivatives, which may be further metabolized 
to nitroso radicals which could be responsi-
ble for the degradation of phospholipids in 
the liver (Pessayre et al., 1985). The highly 
reactive nitrosoalkane derivative is normal-
ly detoxified by glutathione but excessive 
consumption of glutathione stores enables 
the reactive intermediate of erythromycin to 
destroy hepatic cells and other cells (Pes-
sayre et al., 1985).  
Clinical chemistry variables considered 
useful in identifying liver toxicity include 
ALT, AST, sorbitol dehydrogenase (SDA), 
glutamate dehydrogenase (GLDH), total 
bile acids (TBA), lactate dehydrogenase 
(LDH), ornithine carbamyltransferase 
(OCT) and unconjugated bilirubin (UBILI) 
(hepatocellular toxicity); TBA, ALP, gam-
ma glutamyltransferase (GGT), 5’-
nucleotidase (5-NT) and TBILI (hepatobili-
ary toxicity); and glutamate dehydrogenase 
(GLDH), lactate and OCT (mitochondrial 
toxicity; EMEA, 2008). According to 
EMEA (2008), total protein, albumin, tri-
glycerides, cholesterol, glucose and blood 
urea nitrogen, activated partial thrombo-
plastin time (APTT) and prothrombin time 
(PT) can be used as supplementary tests for 
hepatic synthetic functions. Liver disease is 
implicated in cases of elevated levels of 
AST, ALT, LDH, total and direct bilirubin, 
ALP, gamma-glutamyltranspeptidase, 5-
NT, prothrombin time and diminution in 
level of albumin, hepatic demethylation and 
galactose elimination (Cotran et al., 2005). 
Generally, hepatotoxicity is associated 
with diminished activity of cytochrome 
P450 metabolizing enzymes. The hexobar-
bitone-induced hypnosis test is an indirect 
method of assessing the activity of this 
class of enzymes. Hepatic damage resulting 
in reduced metabolizing enzyme activity 
will cause increase in the duration of sleep. 
For example, it has been reported that para-
cetamol and CCl4-induced hepatic injury 
decreased the activity of cytochrome P450 
enzymes and the metabolic functional activ-
ity of hepatocytes, thus delaying barbiturate 
metabolism and excretion of phenobarbi-
tone leading to prolongation of sleeping 
time (Girish et al., 2009; Girish and Pra-
dhan, 2012). According to these authors, 
pretreatment with hepatoprotective phyto-
chemicals restored the phenobarbitone-
induced sleeping time in a dose-related 
fashion.  
CCBs disrupt the movement of Ca2+ 
through calcium channels and are indicated 
for the treatment of hypertension, angina 
pectoris and arrhythmias. Nifedipine, a di-
hydropyridine, possesses high vascular se-
lectivity like other members of its class and 
it is primarily used to reduce systemic vas-
cular resistance and arterial pressure. Mem-
bers of the dihydropyridines class are pri-
marily used to treat hypertension. Verapam-
il is a non-dihydropyridine (phenylalkyla-
mine class) relatively selective for the myo-
cardium and less effective as a systemic 
vasodilator drug. It is used in the treatment 
of angina and arrhythmias. Diltiazem is also 
non-dihydropyridine (benzothiazepine 
class) intermediate in action between nife-
dipine and verapamil. It has both cardiac 
depressant and vasodilator actions. Due to 
the association of hepatotoxicity with dis-
ruption in calcium homeostasis, which may 
result in the activation of many membrane 
damaging enzymes like ATPases, phospho-
lipases, proteases and endonucleases, dis-
ruption of mitochondrial metabolism and 
ATP synthesis and damage of microfila-
ments used to support cell structure (Singh 
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et al., 2011), attempts have been made in 
the past to investigate the modulatory ac-
tions of CCBs in drug-induced hepatotoxi-
city using mostly in vitro models. This 
study was designed to investigate the effect 
of subclinical, clinical and supraclinical 
doses of CCBs (nifedipine, verapamil and 
diltiazem) on isoniazid-rifampicin, zidovu-
dine and erythromycin-induced hepatotoxi-
city in rats. 
In this study, isoniazid-rifampicin, zi-
dovudine and erythromycin significantly 
increased the levels of AST, ALT, ALP and 
total bilirubin while reducing the levels of 
total protein and albumin relative to control. 
Elevation in the level of AST and the liver 
specific ALT result from leakage from 
damaged tissues as a result of hepatocellu-
lar necrosis (Amacher, 2002; Ozer et al., 
2008) while increase in ALP level is as a 
result of overproduction and release in 
blood due to hepatobiliary injury and cho-
lestasis (Ramaiah, 2007). Hepatobiliary in-
jury and cholestasis cause reduced hepatic 
clearance and increase in the level of total 
bilirubin (Dufour et al., 2001). Reduction in 
the level of albumin and total protein are 
consequence of decreased synthetic capaci-
ty as a result of hepatic dysfunction (Thapa 
and Walia, 2007). The standard drug used, 
silymarin, significantly reduced the level of 
AST and increased the level of total protein 
in the isoniazid-rifampicin model; reduced 
the level of ALP and total bilirubin in zi-
dovudine model; and reduced the level of 
AST and ALP in the erythromycin model, 
compared with the hepatotoxicant group. In 
the isoniazid-rifampicin model, the CCBs 
across the doses significantly reduced the 
level of AST, ALT, ALP and total bilirubin, 
while increasing the level of total protein 
and albumin relative to the hepatotoxicant. 
Effect was most prominent at the sub-
clinical and clinical doses for nifedipine; 
supraclinical dose for verapamil; and clini-
cal and supraclinical doses for diltiazem. In 
the zidovudine model, nifedipine most 
prominently reduced the AST and ALP lev-
el at the clinical dose; verapamil most 
prominently reduced AST and increased 
total protein at the supraclinical dose; while 
diltiazem at the subclinical dose most 
prominently reduced AST and total biliru-
bin while increasing total protein compared 
with the hepatotoxicant group. In the eryth-
romycin model, nifedipine at the subclinical 
and supraclinical doses significantly re-
duced AST and ALP levels, respectively 
relative to the hepatotoxicant group. Vera-
pamil across the doses significantly reduced 
the level of total bilirubin, AST and ALP, 
while for diltiazem there was significant 
reduction in ALP level at the clinical dose 
compared with the hepatotoxicant group. 
The action of the CCBs in reducing the lev-
el of liver enzymes and total bilirubin, 
while increasing the level of total protein 
and albumin suggests hepatoprotective ac-
tivity in drug-induced liver injury.  
In respect of the hexobarbitone-induced 
hypnosis test, all the hepatotoxic agents 
used significantly increased the duration of 
sleep compared to control suggesting reduc-
tion in the metabolism of the barbiturate as 
a result of inhibition of cytochrome P450 
activity due to liver damage. Nifedipine at 
the supraclinical dose and silymarin signifi-
cantly reduced the duration of sleep relative 
to the isoniazid-rifampicin only treated 
group. The effects of the CCBs and si-
lymarin were not significant compared to 
the hepatotoxicant in the zidovudine model. 
In the erythromycin model, however, si-
lymarin and the CCBs at all doses used sig-
nificantly reduced the duration of sleep rel-
ative to the hepatotoxicant with effects be-
ing most prominent at the subclinical dose 
for nifedipine and diltiazem, and at the clin-
ical dose for verapamil. The reduction in 
the duration of sleep by the CCBs relative 
to the hepatotoxicant groups suggest ability 
to protect the integrity of the liver and con-
serve the activity of the cytochrome P450 
metabolizing enzymes. 
Oxidative stress is implicated as a 
common pathologic mechanism contrib-
uting to the initiation and progression of 
hepatic damage in a variety of liver disor-
ders (Girish et al., 2009). Mammalian cells 
contain endogenous antioxidant enzymes, 
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including superoxide dismutase (SOD), glu-
tathione peroxidase and catalase (Saeed et 
al., 2005). The initial step in the detoxifica-
tion process is the dismutation of oxygen 
radicals to hydrogen peroxide by SOD. 
Catalase protects cells from oxidative stress 
of hydrogen peroxide by its cleavage to wa-
ter and oxygen (Ookhtens and Kaplowitz, 
1998). Glutathione peroxidase facilitate the 
conjugation of hydrogen peroxide to gluta-
thione (reduced) leading to the generation 
of water and oxidized glutathione (Saeed et 
al., 2005; Akindele et al., 2010). GSH is an 
important biomolecule against chemically 
induced toxicity and can participate in the 
elimination of reactive intermediaries by 
reduction of hydroperoxides in the presence 
of GSH dependent enzymes; it functions as 
a free radical scavenger, a generator of α-
tocopherol and also an important role play-
er in the maintenance of protein sulfhydryl 
group (Meister, 1984; Girish et al., 2009). 
Malondialdehyde is a useful index of lipid 
peroxidation being a major breakdown 
product of lipid peroxides. The engagement 
and overwhelming of antioxidant enzymes 
by free radicals result in the depletion of the 
antioxidant defenses and induction of lipid 
peroxidation evident in elevation of MDA 
level (Akindele et al., 2010). Isoniazid-
rifampicin significantly reduced the level of 
GSH, SOD and CAT while increasing the 
level of MDA relative to control. Silymarin 
significantly reduced the level of MDA 
compared with the hepatotoxicant group. 
Nifedipine at the supraclinical dose signifi-
cantly increased the level of GSH relative 
to the isoniazid-rifampicin only treated 
group. All the CCBs at all doses used sig-
nificantly reduced the level of MDA rela-
tive to the hepatotoxicant group with the 
most prominent effect produced at the su-
praclinical dose for nifedipine and the clini-
cal dose for verapamil and diltiazem. Zi-
dovudine significantly reduced all in vivo 
antioxidants and increased MDA compared 
with the control group. Silymarin signifi-
cantly elevated the level of GSH and CAT 
while reducing MDA compared to zidovu-
dine. Nifedipine at the clinical dose did not 
significantly affect the in vivo antioxidants 
except a significant reduction in CAT at the 
clinical and supraclinical doses relative to 
zidovudine. However, nifedipine at all dos-
es used significantly reduced MDA level 
compared with zidovudine with the most 
prominent effect produced at the clinical 
dose. Verapamil at the clinical dose signifi-
cantly increased the level of SOD but re-
duced CAT level at the supraclinical dose 
compared to the hepatotoxicant group. 
However, the drug at all doses used in this 
study significantly reduced MDA level rela-
tive to zidovudine with the most prominent 
effect produced at the supraclinical dose. 
Diltiazem at the supraclinical dose signifi-
cantly increased GSH level but reduced 
GPx level relative to zidovudine with no 
significant effect on MDA. Erythromycin at 
the dose used in this study did not elicit 
significant changes in the level of antioxi-
dants and MDA. Relative to erythromycin, 
however, silymarin, verapamil at the sub-
clinical dose and diltiazem at the clinical 
dose all increased the level of GSH. The 
elevation of hepatotoxicants diminished in 
vivo antioxidants level and reduction in the 
level of MDA relative to isoniazid-
rifampicin, zidovudine and erythromycin 
suggest that the CCBs counteracted lipid 
peroxidation and preserved the capacity of 
in vivo antioxidants in the liver.  
Observations in the histopathological 
assessment of representative liver samples 
across the groups give further credence to 
the results obtained in the biochemical, an-
tioxidant indices and hypnosis test determi-
nations. 
Although the CCBs used in this study 
demonstrated hepatoprotective activity at 
the supraclinical doses, it is suggested that 
the trial or use of this drugs in humans be 
restricted to the subclinical and clinical 
doses due to the side-effects associated with 
this class of drugs e.g. flushing, dizziness, 
headache, excessive hypotension, constipa-
tion, gingival overgrowth, edema, reflex 
tachycardia, excessive bradycardia, im-
paired electrical conduction/atrioventricular 
nodal block and depressed contractility. 
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CONCLUSION 
The results obtained in this study sug-
gest that the calcium channel blockers (ni-
fedipine, verapamil and diltiazem) possess 
hepatoprotective activity in drug-induced 
hepatotoxicity and they may be beneficial 
at the sub-therapeutic and therapeutic doses 
in situations where stoppage of drug thera-
py as a result of induced hepatotoxicity may 
be critical to therapeutic outcome. 
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